DaVita Inc. (DVAI34)
Sao Paulo Exchange · Brazil · prices in BRL · close of 23 Oct 2026
Key indicators
| Last close | BRL 920.26 |
|---|---|
| 52-week range | 546.63 – 1,253.26 |
| Return, 1 month / 3 months | −2.8% / −23.3% |
| Return, 1 year / 3 years | +33.7% / +148.2% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 50 |
| Volatility (1 year) | 47.2% |
| Worst drawdown (1 year) | -29.0% |
| Average daily value traded | 0.01M BRL |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
DaVita Inc. provides kidney care services, chiefly dialysis treatment for people whose kidneys no longer work well enough on their own. The company runs outpatient dialysis centers and also offers related laboratory, pharmacy and vascular access services, along with home dialysis support. Its patients are individuals with chronic kidney disease and end-stage renal failure, and much of its care is delivered in the United States, with some operations abroad. DaVita is based in Denver, Colorado.
DaVita Inc. is represented on the Sao Paulo Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code DVAI34, with its price quoted in Brazilian reais (BRL). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
DaVita Inc. (DVAI34) trades on the Sao Paulo Exchange in Brazil. It last closed at BRL 920.26 on 23 October 2026.
Its price-based Market X-Ray is 47 out of 100 (a weak price profile), ranking 841 of 1,454 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 33.7% and over the last three months it fell 23.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Sao Paulo Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 50 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | 2.4% | ||
| From 52-week high | -25.7% | ||
| Momentum | 56 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -23.3% | ||
| 6-month return | 17.8% | ||
| 12-month return, skipping the last month | 37.6% | ||
| Stability (higher is calmer) | 42 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 47.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -29.0% | ||
| Liquidity | 33 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M BRL | ||
| Zero-volume days | 23.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −4.0% |
|---|---|
| 1 month | −2.8% |
| 3 months | −23.3% |
| 6 months | +17.8% |
| 1 year | +33.7% |
| 3 years | +148.2% |
| 5 years | +39.8% |
Signals
| 50-day / 200-day average | 927.31 / 898.78 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 21.18 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Sao Paulo Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.